LEVEL UP: Upadacitinib Bests Dupilumab for Moderate-to-Severe Atopic Dermatitis

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Related Keywords

Chicago ,Illinois ,United States ,Jonathan Silverberg ,Health Science ,Drug Administration ,George Washington University School Of Medicine ,Abbvie News Center ,George Washington University Jonathan Silverberg ,Office Of The Commissioner ,George Washington University ,Revolutionizing Atopic Dermatitis ,George Washington University School ,Eczema Area ,Severity Index ,Worst Pruritus Numerical Rating Scale ,Moderate To Severe Atopic Dermatitis ,Efficacy Assessor Blinded Head To Phase ,Movie News ,Evaluate Adverse Events ,Disease Activity Comparing Oral Upadacitinib ,Subcutaneous Dupilumab ,Adult Participants With Moderate ,Severe Atopic Dermatitis ,New Eczema Drug ,